Olmesartan Medoxomil/Amlodipine Zentiva (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxil/Amlodipine combines two antihypertensive agents to lower blood pressure through complementary mechanisms. It is indicated for:

• Hypertension: provides additional blood pressure reduction when monotherapy is insufficient.
• Isolated systolic hypertension in the elderly: improves systolic control while maintaining tolerability.
• Hypertensive patients with concomitant low‑dose calcium‑channel blocker therapy: offers a single‑pill regimen to simplify treatment.

• Olmesartan medoxil blocks the binding of angiotensin II to AT1 receptors, preventing vasoconstriction and aldosterone release. Amlodipine, a dihydropyridine calcium‑channel blocker, inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combination produces additive blood‑pressure‑lowering effects by targeting both the renin‑angiotensin system and peripheral vascular resistance.

Adverse reactions may occur with any antihypertensive combination. Patients should be aware of both common and less frequent events.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness: especially after standing.
• Flushing: transient warmth sensation.
• Fatigue: general tiredness.
• Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips or throat.
• Severe hypotension: symptomatic low blood pressure.
• Hepatic dysfunction: elevated liver enzymes.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: elevated serum potassium levels.
• Myocardial infarction: rare but reported in high‑risk patients.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and adjust if impaired.
• Hepatic function: check liver enzymes in patients with liver disease.
• Electrolytes: monitor potassium, especially if combined with potassium‑sparing agents.
• Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑II blockade.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine may alter the effect of several concomitant medicines. Awareness of major and moderate interactions helps optimise safety.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade: avoid concurrent ACE inhibitors or other ARBs to prevent excess hypotension and renal injury.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase amlodipine levels, raising risk of edema and hypotension.
• Lithium: increased lithium concentrations can lead to toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Diuretics: can potentiate hypotensive response; monitor blood pressure and electrolytes.
• Potassium‑sparing diuretics or supplements: risk of hyper‑kalaemia, especially in renal impairment.